OKYO Pharma (OKYO) Stock Price, News & Analysis

Company Overview

OKYO Pharma Limited is a clinical-stage biotechnology company focused on discovering and developing precision medicines that target G protein-coupled receptors (GPCRs). The company’s research is directed toward treatments for inflammatory, autoimmune and pain-related conditions, including diseases affecting the eye.

OKYO’s lead development program is OK-101, an investigational GPCR-targeted therapy being studied for ocular conditions such as dry eye disease. The company has also explored potential applications of its platform in neuropathic pain and other diseases involving inflammation and immune-system signaling. Its drug candidates remain investigational and are subject to clinical and regulatory evaluation.

OKYO Pharma is based in the United Kingdom and conducts development activities aimed at serving international pharmaceutical and healthcare markets. The company’s shares trade on the Nasdaq Capital Market under the symbol OKYO.

Key Stats

• Today's Range: $1.33 to $1.45
• 50-Day Range: $1.29 to $1.68
• 52-Week Range: $1.26 to $3.20
• Volume: 75,565 shs
• Average Volume: 145,734 shs
• Market Capitalization: $76.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.67
• Consensus Rating: Moderate Buy

OKYO Pharma Stock Analysis - MarketRank™

OKYO Pharma scored higher than 44% of companies evaluated by MarketBeat, and ranked 404th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OKYO Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

OKYO Pharma has a consensus price target of $5.67, representing about 301.9% upside from its current price of $1.41.

Amount of Analyst Coverage

OKYO Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for OKYO Pharma are expected to decrease in the coming year, from ($0.22) to ($0.52) per share.

Price to Book Value per Share Ratio

OKYO Pharma has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.13% of the float of OKYO Pharma has been sold short.

Short Interest Ratio / Days to Cover

OKYO Pharma has a short interest ratio ("days to cover") of 0.46, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OKYO Pharma has recently decreased by 22.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OKYO Pharma does not currently pay a dividend.

Dividend Growth

OKYO Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for OKYO Pharma this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OKYO Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.97% of the stock of OKYO Pharma is held by institutions.

Company Calendar

• Today: 10/02/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OKYO
• CIK: 1849296
• Web: www.okyopharma.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OKYO Pharma: $5.67
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +291.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.43
• Quick Ratio: 2.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 4.83

Miscellaneous

• Outstanding Shares: 52,480,000
• Free Float: 31,247,000
• Market Cap: $76.04 million
• Optionable: Not Optionable
• Beta: 0.06